Back to Search
Start Over
The efficacy and safety of Radiofrequency ablation combined with Lenvatinib plus Sintilimab in Unresectable Hepatocellular Carcinoma: a real-world study.
- Source :
-
BMC cancer [BMC Cancer] 2024 Aug 22; Vol. 24 (1), pp. 1036. Date of Electronic Publication: 2024 Aug 22. - Publication Year :
- 2024
-
Abstract
- Background: The combination of targeted therapy and immunotherapy has improved the clinical outcomes of unresectable hepatocellular Carcinoma (HCC). However, the overall prognosis remains suboptimal. This study aims to evaluate the efficacy and safety of a novel combination of radiofrequency ablation (RFA) with lenvatinib plus sintilimab in unresectable HCC.<br />Methods: In this retrospective study, patients diagnosed with unresectable HCC were included and divided into two cohorts: RFA combined with lenvatinib plus sintilimab (R-L-S group) and lenvatinib plus sintilimab (L-S group). The primary efficacy endpoints were objective response rate (ORR) and progression free survival (PFS). Adverse events were analyzed to assess the safety profiles.<br />Results: The median follow-up periods for the entire cohort were 14.0 months. The R-L-S group (n = 60) had a significantly higher ORR than those with L-S alone (n = 62) (40.0% vs. 20.9%; p = 0.022). Moreover, patients in the R-L-S group had improved median PFS (12 vs. 8 months; p = 0.013) and median overall survival (24 vs. 18 months; p = 0.037), as compared with lenvatinib and sintilimab alone. No significant difference in treatment related adverse event (TRAE) of any grade between the two groups. The most common TRAEs of grade ≥ 3 were fatigue 10.0% (6/60) and hand-foot skin reaction 10.0% (6/60) in the R-L-S group and hand-foot skin reaction 11.3% (7/62) in the L-S group.<br />Conclusion: In unresectable HCC patients, the incorporation of RFA to lenvatinib plus sintilimab demonstrated improved efficacy without compromising safety compared with lenvatinib plus sintilimab alone.<br /> (© 2024. The Author(s).)
- Subjects :
- Humans
Male
Female
Middle Aged
Aged
Retrospective Studies
Combined Modality Therapy
Adult
Treatment Outcome
Aged, 80 and over
Carcinoma, Hepatocellular drug therapy
Carcinoma, Hepatocellular therapy
Carcinoma, Hepatocellular mortality
Carcinoma, Hepatocellular pathology
Carcinoma, Hepatocellular surgery
Quinolines therapeutic use
Quinolines administration & dosage
Quinolines adverse effects
Liver Neoplasms drug therapy
Liver Neoplasms therapy
Liver Neoplasms pathology
Liver Neoplasms surgery
Liver Neoplasms mortality
Phenylurea Compounds administration & dosage
Phenylurea Compounds therapeutic use
Phenylurea Compounds adverse effects
Radiofrequency Ablation methods
Radiofrequency Ablation adverse effects
Antibodies, Monoclonal, Humanized administration & dosage
Antibodies, Monoclonal, Humanized therapeutic use
Antibodies, Monoclonal, Humanized adverse effects
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Antineoplastic Combined Chemotherapy Protocols adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 1471-2407
- Volume :
- 24
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- BMC cancer
- Publication Type :
- Academic Journal
- Accession number :
- 39174912
- Full Text :
- https://doi.org/10.1186/s12885-024-12779-5